SCHEMBL12388665

SCHEMBL12388665

CCOC(COc1cccc2[nH]c(C(=O)OC)cc12)OCC

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2D6 P10635 2/20 0.53
▸ KDM4E B2RXH2 2/20 0.53
▸ ALDH1A1 P00352 1/20 0.53
▸ CYP1A2 P05177 1/20 0.53
▸ HSD17B10 Q99714 1/20 0.53
▸ SRD5A2 P31213 1/20 0.46
▸ HTR1A P08908 2/20 0.45
▸ SLC6A2 P23975 2/20 0.45
▸ ABCB11 O95342 1/20 0.45
▸ ADRA2A P08913 1/20 0.45
▸ PTGS1 P23219 1/20 0.45
▸ OPRM1 P35372 1/20 0.45
▸ DRD3 P35462 1/20 0.45
▸ POLB P06746 2/20 0.45
▸ MAPT P10636 2/20 0.45
▸ MLNR O43193 1/20 0.45
▸ NR1I2 O75469 1/20 0.45
▸ ADRB2 P07550 1/20 0.45
▸ ADRB1 P08588 1/20 0.45
▸ ADRB3 P13945 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7044742 0.86 SRD5A2 (0.53) CYP2D6KDM4EALDH1A1CYP1A2HSD17B10
SCHEMBL12388663 0.85 CYP2D6 (0.59) CYP2D6KDM4EALDH1A1CYP1A2HSD17B10
SCHEMBL12874793 0.81 SRD5A2 (0.50) CYP2D6KDM4EALDH1A1CYP1A2HSD17B10
SCHEMBL10867060 0.79 HTR1A (0.71) CYP2D6KDM4EALDH1A1CYP1A2HSD17B10
SCHEMBL914490 0.79 KDM4E (0.54) CYP2D6KDM4EALDH1A1CYP1A2HSD17B10
SCHEMBL217459 0.78 FLT3 (0.66) KDM4EPOLBMAPTDUSP3PTPN5
SCHEMBL913480 0.78 KDM4E (0.53) CYP2D6KDM4EALDH1A1CYP1A2HSD17B10
SCHEMBL25077801 0.77 SRD5A2 (0.49) CYP2D6KDM4EALDH1A1CYP1A2HSD17B10
SCHEMBL6595625 0.77 SRD5A2 (0.77) CYP2D6KDM4EALDH1A1CYP1A2HSD17B10
SCHEMBL914150 0.76 ULK1 (0.67) CYP2D6KDM4EALDH1A1CYP1A2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8901139-B2 Tricyclic indole derivatives and methods of use thereof MERCK SHARP & DOHME CORP. (US) 2014-12-02 — — US disclosed
US-8901139-B2 Tricyclic indole derivatives and methods of use thereof MERCK SHARP & DOHME CORP. (US) 2014-12-02 — — US disclosed
US-8557848-B2 4,5-ring annulated indole derivatives for treating or preventing of HCV and related viral infections MERCK SHARP & DOHME CORP. (US) 2013-10-15 — — US disclosed
US-8557848-B2 4,5-ring annulated indole derivatives for treating or preventing of HCV and related viral infections MERCK SHARP & DOHME CORP. (US) 2013-10-15 — — US disclosed
US-20110189127-A1 TRICYCLIC INDOLE DERIVATIVES AND METHODS OF USE THEREOF MERCK SHARP & DOHME LLC 2011-08-04 — — US disclosed
US-20100098661-A1 4,5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS SCHERING CORPORATION 2010-04-22 — — US disclosed
US-20100098661-A1 4,5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS SCHERING CORPORATION 2010-04-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100098661-A1 4,5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS ZC3HAV1, IDO1, ZC3HAV1L CYP2D6 133/4885KDM4E 405/4885ALDH1A1 248/4885
US-20110189127-A1 TRICYCLIC INDOLE DERIVATIVES AND METHODS OF USE THEREOF IDO1, IDO2, TPH1 CYP2D6 232/4885KDM4E 1597/4885ALDH1A1 1741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback